I'm not arguing that the pharmaceutical companies are 'good guys', just that the situation was created by the FDA. I think the simplest and safest solution is to reduce compliance costs (which are extremely high in the USA), and allow the new entrants (initially small companies) to rectify the situation. This is not an instantaneous fix, and I will admit that it is a bit unsatisfying, but it's a robust solution.